Background/Objectives: Chronic kidney disease (CKD) is a major cause of morbidity and mortality. Evidence on routine management and patient-reported outcomes in Greece is limited. The SPIRIT study assessed real-world treatment patterns, disease management, and quality of life (QoL) among CKD patients in Greece. Methods...
Evangelia Ntounousi, K. Stylianou, S. Marinaki et al.· Journal of Clinical Medicine· 0 citations
Resistant hypertension, defined as blood pressure (BP) above target despite maximally tolerated doses of at least three antihypertensive agents, including a diuretic, after excluding pseudo-resistance, is common in chronic kidney disease (CKD), and is associated with persistently low rates of BP control [ 1 , 2 ]. Unco...
E. Stambolliu, Carmine Zoccali· Clinical Kidney Journal· 0 citations
A comprehensive overview of emerging pharmacologic and interventional approaches for BP management in nondialysis CKD is provided, highlighting mechanism-driven innovations and their potential clinical translation.
A. Damianaki, P. Iliakis, A. Vakka et al.· Journal of Hypertension· 0 citations
Why injectable lipid-lowering therapies in advanced CKD merits serious consideration is highlighted - not only for their potent and durable lipid-lowering effects, but also for their ability to target other paths that contribute to the excess CV risk not captured by LDL alone.
A. Damianaki, E. Stambolliu, P. Iliakis et al.· Cardiovascular Drugs and The...· 0 citations
In young individuals asymptomatic HMOD is associated with both nocturnal hypertension and non-dipping, however, nighttime BP levels seem to have the primary contributing role.
Aikaterini G. Theodosiadi, A. Kollias, E. Stambolliu et al.· Journal of Hypertension· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
